Insider Trading March 31, 2026

Macy’s Legal Chief Disposes of $48,536 in Shares After Option Exercise

Tracy M. Preston sold 2,736 Macy’s shares March 30 after exercising options two days earlier; company posts a fourth-quarter earnings beat amid mixed analyst reactions

By Marcus Reed M
Macy’s Legal Chief Disposes of $48,536 in Shares After Option Exercise
M

Macy’s Executive Vice President, Chief Legal Officer and Corporate Secretary Tracy M. Preston sold 2,736 shares of Macy’s common stock on March 30, 2026, for approximately $48,536. The sale followed Preston’s exercise of 7,504 options on March 28. The retailer reported stronger-than-expected fourth-quarter fiscal 2025 results, while several analyst firms adjusted price targets and outlooks.

Key Points

  • Tracy M. Preston sold 2,736 shares of Macy’s common stock on March 30, 2026, at an average price of $17.7398, totaling $48,536; sale prices ranged from $17.5550 to $17.8850.
  • Preston exercised options to acquire 7,504 Macy’s shares on March 28, 2026, with an exercise price of $0.
  • Macy’s reported an adjusted diluted EPS of $1.67 and revenue of $7.6 billion for Q4 2025, both above respective forecasts; several analysts adjusted price targets citing margin, valuation and macro concerns.

Insider sale and option exercise

Macy’s (NASDAQ: M) Executive Vice President, Chief Legal Officer and Corporate Secretary Tracy M. Preston sold 2,736 shares of the company’s common stock on March 30, 2026. The shares were disposed of at a weighted price of $17.7398 per share, producing total proceeds of $48,536. The execution prices for the lot ranged from $17.5550 to $17.8850.

Two days earlier, on March 28, Preston exercised options to acquire 7,504 shares of Macy’s common stock at an exercise price of $0.


Market context and valuation metrics

At the time of the transaction, Macy’s stock was trading at $18.1, which the reporting notes is close to its InvestingPro Fair Value of $17.74. The company’s trailing P/E ratio stands at 7.8, and Macy’s yields 4.36% in dividends.

For investors seeking additional valuation and financial detail, a comprehensive Pro Research Report covering Macy’s and more than 1,400 other U.S. equities is available.


Recent financial performance

Macy’s reported adjusted diluted earnings per share of $1.67 for the fourth quarter of fiscal 2025, topping the consensus forecast of $1.56. Revenue for the quarter totaled $7.6 billion, above an expected $7.46 billion.


Analysts weigh in

Despite the quarterly outperformance, a number of analyst teams revised their price targets for Macy’s stock. TD Cowen lowered its target to $20 from $21, citing margin concerns. Telsey reduced its target to $20 from $25, attributing the move to macroeconomic uncertainty. Evercore ISI cut its target to $19 from $21 because of valuation concerns, while also noting that Macy’s same-store sales and EBIT margin exceeded expectations. Jefferies left its Buy rating intact with a $22 price target, acknowledging the earnings beat but pointing out that Macy’s initial fiscal 2026 guidance came in below Wall Street estimates.


What this means

The insider sale and option exercise are factual transactions in corporate filings. Macy’s recent quarterly results showed both revenue and adjusted EPS ahead of forecasts, yet analyst revisions reflect differing views on margins, valuation and near-term guidance. The data cited here provide a snapshot of company activity and market reaction without asserting causality beyond the reported items.

Risks

  • Analyst target reductions and notes of margin concerns could imply investor uncertainty about Macy’s near-term profitability - this impacts the retail and consumer discretionary sectors.
  • Macroeconomic uncertainty cited by some firms may pressure demand and sales trends for retailers, affecting retailer revenue and earnings outlooks.
  • Valuation concerns raised by analysts suggest potential downside in share price expectations, which could influence market sentiment for retail equities.

More from Insider Trading

Daxor CFO Acquires $9,900 in Stock as Company Posts Revenue Gain and Completes $8.1M Offering Mar 31, 2026 C3.ai Director Executes Offset Transactions as Analysts Trim Targets After Weak Quarter Mar 31, 2026 Universal Insurance Director Sells $68k in UVE Stock; Company Posts Strong EPS Beat in Q4 2025 Mar 31, 2026 UTI Legal Chief Disposes $888,115 in Shares as Company Posts Mixed Q1 Results Mar 31, 2026 Ligand Director Executes Option Exercise, Sells $433,842 in Stock as Shares Rally Mar 31, 2026